 Jordana Hoppe
Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 30 | 2026 | 1158 | 7.000 |
Why?
| | Aminophenols | 10 | 2026 | 201 | 2.960 |
Why?
| | Specimen Handling | 5 | 2026 | 186 | 2.200 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 10 | 2026 | 370 | 2.020 |
Why?
| | Quinolones | 10 | 2026 | 201 | 1.990 |
Why?
| | Pyrazoles | 7 | 2026 | 510 | 1.970 |
Why?
| | Indoles | 7 | 2026 | 501 | 1.970 |
Why?
| | Benzodioxoles | 8 | 2026 | 158 | 1.870 |
Why?
| | Pyridines | 7 | 2026 | 605 | 1.800 |
Why?
| | Pyrrolidines | 6 | 2025 | 125 | 1.470 |
Why?
| | Oropharynx | 3 | 2026 | 46 | 1.190 |
Why?
| | Meconium Ileus | 2 | 2026 | 12 | 1.100 |
Why?
| | Sputum | 6 | 2026 | 308 | 1.050 |
Why?
| | Anti-Bacterial Agents | 8 | 2023 | 1915 | 1.040 |
Why?
| | Endpoint Determination | 1 | 2024 | 83 | 0.800 |
Why?
| | Motor Skills | 1 | 2024 | 104 | 0.780 |
Why?
| | Respiratory Tract Infections | 2 | 2025 | 398 | 0.760 |
Why?
| | Self Care | 1 | 2026 | 389 | 0.750 |
Why?
| | Fetal Diseases | 1 | 2024 | 191 | 0.750 |
Why?
| | Advisory Committees | 1 | 2024 | 230 | 0.730 |
Why?
| | Respiratory System Agents | 1 | 2022 | 23 | 0.710 |
Why?
| | Respiratory Function Tests | 3 | 2018 | 547 | 0.710 |
Why?
| | Child | 29 | 2026 | 22657 | 0.690 |
Why?
| | Bacterial Infections | 2 | 2020 | 246 | 0.680 |
Why?
| | Drug Combinations | 4 | 2026 | 392 | 0.640 |
Why?
| | Chloride Channel Agonists | 4 | 2025 | 109 | 0.640 |
Why?
| | Respiratory System | 2 | 2019 | 149 | 0.600 |
Why?
| | Child, Preschool | 17 | 2026 | 11799 | 0.570 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 1054 | 0.570 |
Why?
| | Drug Prescriptions | 1 | 2020 | 285 | 0.550 |
Why?
| | Tomography | 1 | 2018 | 45 | 0.540 |
Why?
| | Quality Improvement | 2 | 2024 | 1291 | 0.530 |
Why?
| | Lung Diseases | 2 | 2023 | 787 | 0.460 |
Why?
| | Adolescent | 20 | 2026 | 22453 | 0.390 |
Why?
| | Humans | 37 | 2026 | 144957 | 0.390 |
Why?
| | Feasibility Studies | 3 | 2026 | 1095 | 0.380 |
Why?
| | Candida | 4 | 1997 | 44 | 0.370 |
Why?
| | Mutation | 6 | 2023 | 4099 | 0.360 |
Why?
| | Lung | 3 | 2020 | 4109 | 0.340 |
Why?
| | Male | 22 | 2026 | 72406 | 0.330 |
Why?
| | Female | 24 | 2026 | 78376 | 0.330 |
Why?
| | Quinolines | 3 | 2026 | 193 | 0.300 |
Why?
| | Microbiota | 1 | 2017 | 781 | 0.290 |
Why?
| | Administration, Oral | 3 | 2023 | 848 | 0.290 |
Why?
| | Treatment Outcome | 6 | 2025 | 11695 | 0.280 |
Why?
| | Bacteriological Techniques | 3 | 1998 | 68 | 0.270 |
Why?
| | Pharynx | 2 | 1998 | 59 | 0.250 |
Why?
| | Infant | 11 | 2026 | 10039 | 0.240 |
Why?
| | Quality of Life | 1 | 2018 | 3192 | 0.230 |
Why?
| | Telemedicine | 2 | 2026 | 948 | 0.230 |
Why?
| | Antifungal Agents | 2 | 1997 | 149 | 0.220 |
Why?
| | Pyrroles | 1 | 2026 | 218 | 0.220 |
Why?
| | Cyclopropanes | 1 | 2025 | 83 | 0.220 |
Why?
| | Deoxyribonuclease I | 1 | 2024 | 41 | 0.220 |
Why?
| | Cough | 1 | 2025 | 124 | 0.210 |
Why?
| | Bone Marrow Transplantation | 2 | 1997 | 294 | 0.210 |
Why?
| | Mouth | 2 | 1995 | 88 | 0.210 |
Why?
| | Motor Skills Disorders | 1 | 2024 | 25 | 0.210 |
Why?
| | Forced Expiratory Volume | 2 | 2024 | 449 | 0.200 |
Why?
| | Staphylococcus aureus | 2 | 2026 | 460 | 0.200 |
Why?
| | Bacteria | 3 | 2018 | 889 | 0.190 |
Why?
| | Ciliary Motility Disorders | 1 | 2023 | 24 | 0.190 |
Why?
| | Calreticulin | 1 | 2022 | 22 | 0.180 |
Why?
| | HMGB Proteins | 1 | 2022 | 17 | 0.180 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2022 | 40 | 0.180 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2022 | 89 | 0.180 |
Why?
| | Bronchiectasis | 1 | 2023 | 112 | 0.170 |
Why?
| | Feces | 2 | 1995 | 513 | 0.170 |
Why?
| | Recombinant Proteins | 1 | 2024 | 1371 | 0.170 |
Why?
| | Pseudomonas aeruginosa | 2 | 2021 | 356 | 0.170 |
Why?
| | Leptin | 1 | 2022 | 245 | 0.160 |
Why?
| | Aminopyridines | 1 | 2021 | 127 | 0.160 |
Why?
| | Adult | 12 | 2026 | 40506 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 319 | 0.150 |
Why?
| | Pilot Projects | 3 | 2023 | 1890 | 0.150 |
Why?
| | United States | 3 | 2024 | 15988 | 0.150 |
Why?
| | Patient Compliance | 2 | 1999 | 589 | 0.140 |
Why?
| | Electric Impedance | 1 | 2018 | 111 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2026 | 3415 | 0.130 |
Why?
| | Proteome | 1 | 2022 | 518 | 0.130 |
Why?
| | Fungi | 1 | 1998 | 161 | 0.130 |
Why?
| | Lipids | 1 | 2022 | 710 | 0.130 |
Why?
| | Candidiasis | 1 | 1997 | 64 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 1999 | 203 | 0.120 |
Why?
| | Infant, Newborn | 3 | 2024 | 6434 | 0.120 |
Why?
| | Mycoses | 1 | 1997 | 88 | 0.120 |
Why?
| | Cohort Studies | 2 | 2017 | 5965 | 0.110 |
Why?
| | Drug Monitoring | 1 | 1999 | 395 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 845 | 0.110 |
Why?
| | Pregnancy | 2 | 2026 | 7191 | 0.110 |
Why?
| | Proteomics | 1 | 2022 | 1195 | 0.110 |
Why?
| | Mastoiditis | 1 | 1994 | 10 | 0.110 |
Why?
| | Colony Count, Microbial | 3 | 1999 | 122 | 0.100 |
Why?
| | Inflammation | 2 | 2023 | 2880 | 0.100 |
Why?
| | Genotype | 1 | 2018 | 1835 | 0.100 |
Why?
| | Prevalence | 1 | 2019 | 2836 | 0.090 |
Why?
| | Population Surveillance | 1 | 1994 | 485 | 0.080 |
Why?
| | Longitudinal Studies | 2 | 2015 | 2947 | 0.080 |
Why?
| | Disease Management | 1 | 2014 | 647 | 0.080 |
Why?
| | Disease Progression | 1 | 2017 | 2852 | 0.080 |
Why?
| | Young Adult | 3 | 2026 | 14126 | 0.070 |
Why?
| | Hexuronic Acids | 2 | 1998 | 23 | 0.070 |
Why?
| | Glucuronic Acid | 2 | 1998 | 25 | 0.060 |
Why?
| | Evaluation Studies as Topic | 2 | 1998 | 166 | 0.060 |
Why?
| | Alginates | 2 | 1998 | 49 | 0.060 |
Why?
| | Culture Media | 2 | 1998 | 161 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2020 | 17101 | 0.060 |
Why?
| | Candida albicans | 2 | 1997 | 61 | 0.060 |
Why?
| | Amphotericin B | 2 | 1997 | 37 | 0.060 |
Why?
| | Antibodies, Fungal | 2 | 1995 | 9 | 0.060 |
Why?
| | Saline Solution, Hypertonic | 1 | 2024 | 42 | 0.050 |
Why?
| | Postoperative Complications | 1 | 1997 | 2920 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2025 | 289 | 0.050 |
Why?
| | Dyneins | 1 | 2023 | 35 | 0.050 |
Why?
| | Leukocyte Elastase | 1 | 2023 | 75 | 0.050 |
Why?
| | Chlorides | 1 | 2023 | 142 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2023 | 575 | 0.050 |
Why?
| | Peptide Hydrolases | 1 | 2023 | 105 | 0.040 |
Why?
| | Alleles | 1 | 2023 | 881 | 0.040 |
Why?
| | Suspensions | 1 | 1999 | 29 | 0.040 |
Why?
| | False Negative Reactions | 1 | 1999 | 61 | 0.040 |
Why?
| | Cephalosporins | 1 | 1999 | 47 | 0.040 |
Why?
| | Neoplasms | 1 | 1995 | 2884 | 0.040 |
Why?
| | Penicillins | 1 | 1999 | 61 | 0.040 |
Why?
| | Macrolides | 1 | 1999 | 69 | 0.040 |
Why?
| | False Positive Reactions | 1 | 1999 | 122 | 0.040 |
Why?
| | Bacillus subtilis | 1 | 1999 | 69 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 1217 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3608 | 0.030 |
Why?
| | Aspergillus fumigatus | 1 | 1997 | 25 | 0.030 |
Why?
| | Transplantation, Isogeneic | 1 | 1997 | 17 | 0.030 |
Why?
| | Aspergillosis | 1 | 1997 | 23 | 0.030 |
Why?
| | Data Collection | 1 | 1999 | 635 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 1997 | 292 | 0.030 |
Why?
| | Agar | 1 | 1995 | 11 | 0.030 |
Why?
| | Mycology | 1 | 1995 | 5 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 1997 | 415 | 0.030 |
Why?
| | Natamycin | 1 | 1995 | 2 | 0.030 |
Why?
| | Nystatin | 1 | 1995 | 3 | 0.030 |
Why?
| | Cellulose | 1 | 1995 | 58 | 0.030 |
Why?
| | Fluconazole | 1 | 1995 | 23 | 0.030 |
Why?
| | Premedication | 1 | 1995 | 42 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 2065 | 0.030 |
Why?
| | Aged | 2 | 2026 | 25947 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 69 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1990 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1997 | 1311 | 0.030 |
Why?
| | Germany | 1 | 1994 | 138 | 0.030 |
Why?
| | Causality | 1 | 1994 | 126 | 0.020 |
Why?
| | Genetic Markers | 1 | 2014 | 331 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2026 | 6053 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 409 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 1997 | 579 | 0.020 |
Why?
| | Patient Admission | 1 | 1994 | 218 | 0.020 |
Why?
| | Otitis Media | 1 | 1994 | 181 | 0.020 |
Why?
| | Acute Disease | 1 | 1994 | 1031 | 0.020 |
Why?
| | Incidence | 1 | 1994 | 2883 | 0.020 |
Why?
| | Middle Aged | 1 | 2026 | 35928 | 0.010 |
Why?
| | Prospective Studies | 1 | 1995 | 7997 | 0.010 |
Why?
|
|
Hoppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|